EP Patent

EP4074317A1 — Phosphorus derivatives as novel sos1 inhibitors

Assigned to Bayer AG · Expires 2022-10-19 · 4y expired

What this patent protects

The present invention covers phosphorus derivatives of general formula (I) :in which R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, X<sub>1</sub>, X<s…

USPTO Abstract

The present invention covers phosphorus derivatives of general formula (I) :in which R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, X<sub>4</sub> and Y are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of of hyperproliferative disorders, especially diseases associated with SOS1, as a sole agent or in combination with other active ingredients.

Drugs covered by this patent

Patent Metadata

Patent number
EP4074317A1
Jurisdiction
EP
Classification
—
Expires
2022-10-19
Drug substance claim
No
Drug product claim
No
Assignee
Bayer AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.